Table 2. On-treatment medications and risk factor control of overall patients.

	Caucasians (n=3,309)	African-Americans (n=170)	P-value
Concomitant medications
Statin use (%)	94.7	92.9	0.33
Beta-blocker use (%)	76.4	78.8	0.46
Aspirin use (%)	94.5	88.8	0.002
ACE inhibitor use (%)	55.1	52.4	0.48
Calcium-channel blocker use (%)	37.7	48.2	0.006
Oral anti-diabetic drug (%)	28.0	43.5	<0.001
Insulin (%)	9.3	19.4	<0.001
On-treatment parameters
Total cholesterol (mmol/L) (mean ± SD)	4.2±0.9	4.4±0.9	0.06
LDL-cholesterol (mmol/L) (mean ± SD)	2.2±0.7	2.4±0.7	0.006
HDL-cholesterol (mmol/L) (mean ± SD)	1.2±0.4	1.3±0.4	0.001
Triglyceride (mmol/L) [median (interquartile range)]	1.5 (1.1, 2.0)	1.2 (0.9, 1.6)	<0.001
Non-HDL cholesterol (mmol/L)	2.9±1.0	2.9±1.1	0.75
CRP (mg/dL) [median (interquartile range)]	2.0 (1.0, 4.4)	2.9 (1.3, 7.0)	<0.001
HbA1c (%) (mean ± SD)	6.4±1.2	7.3±1.7	<0.001
Fasting glucose (mmol/L) (mean ± SD)	6.4±1.9	6.7±2.3	0.17
Systolic blood pressure (mmHg) (mean ± SD)	128±13	133±15	<0.001
Diastolic blood pressure (mmHg) (mean ± SD)	76±7	78±7	0.001
The prevalence of patients with optimal controlled risk
LDL-C < 2.1 mmol/L (%)	42.8	34.1	0.02
CRP < 2.0 mg/dL (%)	49.3	37.3	0.004
Systolic blood pressure <130 mmHg (%)	58.9	44.2	<0.001

ACE, angiotensine converting enzyme; CRP, c-reactive protein; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein